Clinical trial
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are…
NCT00002048 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002048 |
|---|---|
| Title | The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) |
| Official title | The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Lymphatic Disease, HIV Infections |
| Intervention type | Drug |
| Interventions | Zidovudine |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: